Inloggad som:

Cellprotect-ISA-HC-NK

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

Cellprotect-ISA-HC-NK
An open, randomised, controlled phase II trial ofCellProtect in combination with isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment
An open, randomised, controlled phase II trial ofCellProtect in combination with isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 3
Palliativ
Akademisk

Studien ändrades senast av: studyjohanna (2021-07-13)

Tillbaka till listan